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CC BY-NC-ND license (http://creativeAbstract Our aim was to evaluate the relationship between the success of methotrexate
treatment and b-hCG levels in progressive tubal ectopic pregnancies. We defined a retrospec-
tive cohort of 394 progressive tubal ectopic pregnancy patients treated with methotrexate. A
single-dose methotrexate protocol using 50 mg/m2 was administered to patients with progres-
sive tubal ectopic pregnancy. Surgery was performed in patients who exhibited signs of acute
abdomen due to tubal rupture. Of 394 patients that received methotrexate treatment, 335
(84.6%) responded to medical treatment, while the remaining 59 (15.36%) underwent surgery
due to treatment failure. b-hCG levels in the failure group were significantly higher as
compared with the success group at Day 1, Day 4, and Day 7 (2116 3157 vs. 4178 3422,
2062  3551 vs. 4935  4103, and 1532  3007 vs. 3900  4783, respectively). The receiver
operating characteristics curve for b-hCG levels at Day 1 was 0.738, with a cutoff value of
1418 mIU/mL, while sensitivity and specificity values reached the optimum for treatment suc-
cess (83.1% and 59.4%, respectively). Medical treatment with methotrexate achieved an
85.02% success rate for the treatment of progressive tubal ectopic pregnancy, while success
rates for medical treatment decreased significantly when initial b-hCG levels were
>1418 mIU/mL.
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Ectopic pregnancy (EP) occurs inw1e2% of all pregnancies
[1]. Assisted reproductive techniques, a history of pelvic
inflammatory disease, tubal surgery, and a history of EP are
established risk factors for EP [2]. Patients showing a
decline or plateau in b-hCG levels are managed expec-
tantly. In hemodynamically stable patients, treatment
during this period involves medical therapy if the b-hCG
levels plateau or increase. In hemodynamically unstable
patients with signs of acute abdomen or rupture of EP, the
only treatment choice is surgery [3].
Medical treatment includes the use of methotrexate,
which is currently used worldwide and is the most efficient
agent. Methotrexate is preferred, because it has few side
effects and high efficiency. Various administration pro-
tocols are used in clinical practice involving single-, two-,
and fixed-dose regimens [3]. Monitoring serial b-hCG levels
and the clinical findings associated with tubal rupture, such
as hemodynamic instability and severe pain, are helpful in
evaluating the efficacy of medical therapy. Serial b-hCG
monitoring can also be used to differentiate spontaneously
resorbing EP from progressive EP. Single-dose methotrexate
is the most common treatment protocol, with the main
purpose being achieving maximum success from adminis-
tering the lowest dose possible with minimal side effects.
This study investigated the success of methotrexate
therapy and factors affecting treatment success in patients
with progressive tubal ectopic pregnancy (PTEP).
Methods
This retrospective study was conducted at Department of
Obstetrics and Gynecology, Tepecik Education and
Research Hospital, and approval was obtained from the
institutional ethics committee. The medical records of
patients with tubal EP between January 2009 and
September 2014 were reviewed retrospectively.
At our hospital, the treatment of patients pre-diagnosed
with EP is guided by a treatment protocol in which hemo-
dynamically stable patients are monitored with serial b-
hCG measurements and ultrasonography. Patients with a
> 15% daily decrease in serial b-hCG measurements are
regarded as having spontaneously resorbing EP and moni-
tored expectantly. Hemodynamically unstable patients
with positive embryonic cardiac activity and those with
signs of intra-abdominal bleeding, such as pain, undergo
surgery. Patients with an inadequate increase or< 15%
decrease in serial b-hCG measurements are regarded as
progressive EP, and endometrial curettage is performed.
After endometrial curettage, daily serial b-hCG measure-
ments are continued, and methotrexate is given to patients
in whom b-hCG levels plateau (daily decrease< 15%) or
increase. Patients with a contraindication for methotrexate
treatment (abnormal liver or kidney function tests, pres-
ence of intrauterine pregnancy, active pulmonary disease,
peptic ulcer, or presence of hematological or immunolog-
ical disorder) and those who request surgery undergo
elective surgery.
Methotrexate treatment is tailored according to the
single-dose protocol (50 mg/m2) and administeredintramuscularly after calculating the body surface area. The
day of administration is regarded as Day 1, and the serum b-
hCG levels are determined onDay 4 andDay 7. Patientswith a
> 15% decrease in the b-hCG level between Day 4 and Day 7
are considered to have responded tomedical therapy, and b-
hCG levels are measured weekly until they fall below 5 mIU/
mL. Patients who do not show a > 15% decrease in b-hCG
levels between Day 4 and Day 7 and whose levels plateau or
increase are administered an additional dose of metho-
trexate (50 mg/m2) intramuscularly. Patients with an in-
crease in serum b-hCG levels, despite two doses of
methotrexate, and those with hemodynamic instability or
severe abdominal pain undergo surgery, which is regarded as
indicating medical treatment failure. This study evaluated
patients who were diagnosed with progressive EP according
to the above-mentioned protocol and who received metho-
trexate. The patients in the study were divided into success
and failure groups and were compared in terms of age,
gravida, parity, size of EP, b-hCG levels at Day 1, Day 4, and
Day 7, and the need for an additional methotrexate dose.
IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY,
USA) and MedCalc 14 software packages (https://www.
medcalc.org/) were used in the analysis of the study data.
The continuous variables were expressed mean standard
deviation, median (q1 e q3), and the categorical variables
were expressed as percentage. The Shapiro-Wilk test was
used to determine if the variables were normally distrib-
uted. The independent-sample t test was used in the com-
parison of the two groups that showed normal distributions.
The ManneWhitney U test was used to compare the two
groups that did not show normal distributions. Receiver
operating characteristic (ROC) analysis was used to deter-
mine the appropriate cut-off values for independent
markers and calculate sensitivity and specificity. The level of
statistical significance was established at p< 0.05.Results
The study enrolled 394 patients who were admitted with a
prediagnosis of PTEP, and whose diagnosis was confirmed
histopathologically by endometrial curettage. As per our
clinical protocol, 335 of the 394 patients who were deemed
eligible for methotrexate therapy were monitored until the
b-hCG levels returned to normal; this group was regarded as
the success group. The remaining 59 patients underwent
surgery for severe abdominal pain, acute abdomen, or he-
matological instability and were regarded as the failure
group (Figure 1). There were no significant differences
between the success and failure groups in terms of de-
mographic and clinical characteristics (Table 1).
The b-hCG levels on day 1 were significantly lower in the
patients who responded to medical treatment
(2116 3157 mIU/mL vs. 4178 3422 mIU/mL, p< 0.0001).
Significant differences were also seen in the mean b-hCG
value between the success and failure groups at Day 4
(pZ 0.0001) and Day 7 (pZ 0.0001; Table 2).
ROC analysis was used to identify a specific cut-off for
the maximum success rate based on these levels. ROC an-
alyses of the Day 1 b-hCG levels revealed that the optimum
cut-off point for the b-hCG level was 1418 mIU/mL
(area under ROC curveZ 0.738; sensitivityZ 83.1%,
Figure 1. Flow chart of patients treated with single-dose methotrexate protocol.
Table 1 Characteristics of 394 women treated with methotrexate.
Characteristics Methotrexate success (nZ 335) Methotrexate failure (nZ 59) p
Age (y) 30.44 5.8 29.8 5.3 0.468*
31.00 (26.00e34.00) 30.00 (27.00e33.00)
Parity (n) 1.03 0.92 1.28 1.21 0.64**
1.00 (0.00e2.00) 1.00 (0.00e2.00)
Gravidity (n) 2.57 1.34 2.84 1.34 0.144**
2.00 (2.00e3.00) 3.00 (2.00e4.00)
EU*** mass size, (mm) 19.6 12.8 22.12 14.5 0.185**
15.00 (10.00e25.00) 17.00 (11.00e30.00)
* Independent t test.
** ManneWhitney U test.
*** Ectopic pregnancy.
Data are presented as mean SD and median (q1eq3).
EUZ extrauterine; SDZ standard deviation.
Table 2 b-hCG levels in success and failure groups on Day 1, Day 4, Day 7, and Day 11.
Methotrexate success,
mean SD, [median (q1eq3)]
n Methotrexate failure,
mean SD, [median (q1eq3)]
n p
Day 1 2116 3157 335 4178 3422 59 <0.0001*
1333 (535e3857) 2532 (498e4643)
Day 4 2062 3551 335 4935 4103 47 <0.0001*
1779 (616e5615) 3361 (624e6447)
Day 7 1532 3007 335 3900 4783 31 <0.0001*
1566 (533e5032) 2941 (555e7552)
Day 11 2130 3958 58 1813 2751 12 0.793*
902 (294e3108) 499 (123e2246)
* ManneWhitney U test.
b-hCGZ beta-human chorionic gonadotropin; SDZ standard deviation.
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All of these parameters suggested good predictive accuracy
for this cut-off. For clinical practice, a cut-off value
of< 1418 mIU/mL b-hCG on Day 1 can be considered a good
predictor of successful medical management with metho-
trexate (Figure 2). Table 3 shows the success rates and
corresponding b-hCG values.The examination of factors predicting the success of
medical treatment showed a 6.86% increase in b-hCG levels
between Day 1 and Day 4 associated with an 8.3-fold in-
crease in the probability of treatment failure, with 69.58%
sensitivity and 78.72% specificity.
Of the 394 patients in this study, 325 (82.48%) received
single-dose methotrexate, and 69 patients (17.5%) required
Figure 2. Receiver operating characteristic curve for Day 1
b-hCG levels following a single dose of methotrexate.
Table 3 Success rates for methotrexate according to
b-hCG level.
b-hCG level
(mIU/mL)
Cases (n) Failures (n) Success rate (%)
0e500 126 6 95.23
500e1000 59 4 93.22
1000e1500 29 2 93.10
1500e2000 33 5 84.84
2000e2500 23 5 78.26
2500e3500 32 7 78.12
3500e4500 20 7 65
> 4500 72 23 68.05
Total 394 59 85.02
b-hCGZ beta-human chorionic gonadotropin.
Table 4 Characteristics and b-hCG levels of the patients
treated with single- and additional dose methotrexate.
Single dose n Additional
dose
n p*
Age (y) 30.3  5.7 325 30.5  5.8 69 0.746
Gravida 2.6  1.3 325 2.6  1.3 69 0.836
Parity 1.07  0.98 325 1.07  0.92 69 0.990
Day 1 b-hCG 2374  3201 325 2661  3631 69 0.509
Day 4 b-hCG 2122  3164 313 3748  5496 69 0.001
Day 7 b-hCG 1339  2558 297 3425  4980 69 <0.001
Days 1e4
b-hCG (%)
11.02  42.5 312 36.43  35.05 69 <0.001
Days 4e7
b-hCG (%)
39.27  25.3 294 9.08  17 69 <0.001
Days 1e7
b-hCG (%)
44.20  40.3 288 24.16  40.2 69 <0.001
Data are presented as mean  SD.
* ManneWhitney U test.
b-hCGZ beta-human chorionic gonadotropin; SDZ standard
deviation.
Table 5 Characteristics and b-hCG levels of the patients
treated by additional methotrexate dose.
Additional
methotrexate dose
Success group
(nZ 57)
Failure group
(nZ 12)
p*
Age (y) 30.8  6 28.9  5 0.257
Gravida 2.59  1.46 2.83  1.02 0.356
Day 1 b-hCG 2525  3697 3309  3372 0.429
Day 4 b-hCG 3602  5676 4442  4697 0.393
Day 7 b-hCG 3280  5097 4113  4519 0.429
Days 1e4 b-hCG
change (%)
36.8  37.2 34.5  23.2 0.975
Days 4e7 b-hCG
change (%)
8.3  16.3 12.65  20 0.438
Days 7e11 b-hCG
change (%)
37.1  28 32.7  24 0.590
Data are presented as mean  SD.
* ManneWhitney U test.
b-hCGZ beta-human chorionic gonadotropin; SDZ standard
deviation.
320 A. Dogan et al.an additional methotrexate dose. A comparison of these
two groups found no significant differences in age, gravida,
parity, or initial b-hCG levels (Table 4). There was a 7.93-
fold increase in the need for an additional methotrexate
dose, with 82.61% sensitivity and 75.81% specificity when
the increase in b-hCG levels from Day 1 to Day 4 predicting
the need for additional methotrexate dose was 8.25%.
When the mean decrease in the b-hCG level from Day 1 to
Day 4 was 9.87%, a 5.65-fold decrease was observed in the
need for an additional methotrexate dose, with 77.7%
sensitivity and 82.9% specificity (p< 0.001).
Of the 335 patients who responded to medical treat-
ment, 57 received an additional methotrexate dose, and 12
of 59 in the failure group (all had tubal rupture) received an
additional methotrexate dose. The mean age and gravida
did not differ significantly between these patient groups,and there were no significant differences between the
groups in terms of the b-hCG level at baseline, at Day 4, or
in comparisons of Day 1 and Day 4, Day 4 and Day 7, and Day
7 and Day 11 (Table 5).
Discussion
With advances in imaging technology, EP is being detected
earlier in pregnancy. With the introduction of methotrexate
into clinical practice, surgical treatment has been mostly
replaced by medical treatment. Treatment protocols that
were approvedw2 decades ago are still effective [4]. In an
article published by the American Society for Reproductive
Medicine in 2013, hemodynamic instability (findings of
tubal rupture) and severe abdominal pain increasing in
Ectopic pregnancy and methotrexate 321severity, regardless of any change in b-hCG levels, and a
> 53% increase in b-hCG levels after the second dose in
single-dose regimens and after the fourth dose in multiple-
dosing regimens are regarded as indicators of a poor
response to medical treatment [5].
Of the study patients, all of whom had PTEP, 59 under-
went surgery for tubal rupture, and 335 patients were
treated without requiring surgical intervention, for a suc-
cess rate of 85.02%. Levin et al. [6] monitored asymptom-
atic patients with plateauing b-hCG levels and a
prediagnosis of tubal EP for up to 5 days (mean, 2.65 days)
to rule out spontaneously resorbing EP and to determine
the true efficiency of methotrexate therapy in PT preg-
nancies. They administered methotrexate to patients with
plateauing or sustained increases in b-hCG levels, referring
to this approach as “watchful waiting” and reporting an 87%
success rate for methotrexate treatment [6,7]. Sagiv et al.
[8] reported success rates for methotrexate treatment in
patients with asymptomatic tubal EP of 88% if b-hCG
was 1000 mIU/mL and 71% if b-hCG was between
1000 mIU/mL and 2000 mIU/mL. They also reported tubal
rupture in all members of the failure group, similar to the
case in our study [8].
In this study, the mean initial b-hCG level was signifi-
cantly lower in the success group (2116 3157 mIU/mL) as
compared with the failure group (4178 3422 mIU/mL).
The analysis performed to evaluate which b-hCG level was
associated with a decrease in the efficiency of medical
therapy indicated a cut-off value of 1418 mIU/mL, with
83.1% sensitivity and 59.4% specificity. When the success
rate was evaluated according to the range of b-hCG values,
the success rate declined from 90% to 80% for the cut-off
value determined in the analysis (Table 3). Additionally,
b-hCG values at Day 4 and Day 7 were lower in the success
group. Many studies evaluated biochemical and sonographic
parameters to determine predictors of the efficiency of
medical therapy in patients with EP [9,10]. Yildirim et al.
[11] found that an initial b-hCG level of 2000 mIU/mL
predicted the response to treatment, and that values above
this cut-off point were associated with a decreased success
rate. Similarly, Menon et al. [12] reviewed the results of 500
patients in five studies and reported a cut-off value of
5000 mIU/mL, and suggested that medical treatment
administered to patients with higher values was more likely
to be associated with treatment failure. Nowak-Markwitz
et al. [13] suggested a more precise cut-off value and re-
ported a higher failure rate at > 1790 mIU/mL, while Helmy
et al. [14] reported a cut-off value of 2121 mIU/mL. Natale
et al. [15] suggested that changes in b-hCG levels reflected
differences in folinic acid metabolism across individuals.
Additionally, methotrexate administration caused mitotic
arrest in cytotrophoblasts, but b-hCG production was
maintained in syncytiotrophoblasts. The authors concluded
that b-hCG values at the initial dose and after metho-
trexate administration did not change significantly in the
first few days [15].
Patient management based on the changes in b-hCG
values at Day 4 and Day 7 after methotrexate therapy re-
quires prolonged in-hospital patient monitoring. This
approach not only causes patient anxiety, but also in-
creases the treatment cost per patient. A reduction in this
period would decrease the costs and avoid anxiety.Therefore, the efficacy of serial b-hCG measurements at
Day 1 and Day 4 for predicting treatment success has long
been studied. Agostini et al. [16] reported that a 20%
decrease in b-hCG level predicted treatment success with a
97% positive-predictive value. Similarly, Ustunyurt et al.
[17] reported that a 22% decrease in b-hCG level predicted
treatment success. Celik et al. [18] studied 93 patients and
reported a 4.94-fold increase in treatment failure associ-
ated with at least a 9.08% decrease in b-hCG levels from
Day 1 to Day 4. Following methotrexate administration, a
slight increase in b-hCG levels is usually expected in the
first few days [18]. In our study group, ROC and logistic
regression analysis of the change in b-hCG levels from Day 1
to Day 4 showed that a > 6.86% increase in b-hCG level was
associated with an 8.3-fold increase in the probability of
treatment failure, with 69.58% sensitivity and 78.7% spec-
ificity. The decrease in b-hCG levels did not significantly
predict treatment success (pZ 0.83). Following the initial
dose of methotrexate therapy, the need for an additional
methotrexate dose is another factor causing patient anxi-
ety and increased length of hospital stay. In our series, 69
patients (17.5%) required an additional methotrexate dose.
The intragroup analysis of patients who received an addi-
tional methotrexate dose showed no significant difference
between the success and failure groups in terms of initial b-
hCG levels; therefore, a cut-off value could not be deter-
mined to predict treatment success. Cohen et al. [19]
investigated the factors affecting treatment success in
patients requiring an additional methotrexate dose, and
unlike our results, they reported a significant difference
between the initial b-hCG values of the success and failure
groups and suggested that the success rate of an additional
methotrexate dose was lower if the cut-off value was
2234 mIU/mL.
In this study, when patients who received methotrexate
therapy were divided into single-dose and additional dose
groups, regardless of the success rate, there was no sig-
nificant difference between the two groups in terms of the
initial b-hCG values. However, in the additional dose group,
a > 8.2% increase in b-hCG levels from Day 1 to Day 4 was
associated with a 7.93-fold increase in the probability of
receiving an additional dose (sensitivity 82.61%, specificity
75.81%, pZ 0.0017). A 9.87% decrease in b-hCG levels from
Day 1 to Day 4 was associated with a 5.65-fold decrease in
risk. In a study of 88 patients, Atkinson et al. [20] empha-
sized that a decrease in the b-hCG level from Day 4 to Day 7
was superior to a decrease from Day 1 to Day 4 at predicting
the need for an additional methotrexate dose. We did not
make such a comparison, but instead evaluated the use-
fulness of changes from Day 1 to Day 4 for predicting the
need for an additional methotrexate dose. Although the
percentage changes found in our study were not sufficiently
high to be used in daily practice, these findings were
beneficial from the perspective of providing insight into the
need for additional doses.
In conclusion, with one of the largest reported patient
series, our study suggested a higher success rate in patients
with PTEP and lower initial b-hCG levels, and the chance of
success was lower above a dose cut-off value of 1418 mIU/
mL. Additionally, the chance of success and the need for
additional methotrexate doses could be predicted based on
changes in b-hCG from Day 1 to Day 4.
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